FDA’s Pulmonary-Allergy Drugs Advisory Committee
Executive Summary
Will discuss Warner-Lambert's NDA for Pro-Air (procaterol) metered- dose inhaler on Feb. 25 and the NDA for Glaxo's Serevent (salmeterol xinafoate) inhalation on Feb. 26. The discussion of the two beta agonists for treatment of asthma follows up on the committee's December 1991 conclusion that more study was needed on the association of increased mortality and morbidity with bet agonist use. The meeting will take place at Parklawn.